Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)

Clinical Trial ID NCT01472029

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
2	HER2-positive gastric cancer.	Gastric Cancer	2013	1.32
3	Targeted therapy in gastroesophageal cancers: past, present and future.	Gastroenterol Rep (Oxf)	2015	0.85
4	Current status of novel agents in advanced gastroesophageal adenocarcinoma.	J Gastrointest Oncol	2015	0.83
5	Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.	Therap Adv Gastroenterol	2012	0.83
6	Neoadjuvant or adjuvant therapy for gastric cancer.	World J Gastrointest Oncol	2015	0.82
7	Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.	World J Gastroenterol	2013	0.82
8	New advances in targeted gastric cancer treatment.	World J Gastroenterol	2016	0.81
9	Recent advances in the HER2 targeted therapy of gastric cancer.	World J Clin Cases	2015	0.80
10	Abstracts of New Developments in Hematology and Oncology in 2011. Guangzhou, China. December 25-26, 2011.	J Hematol Oncol	2012	0.75
11	The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.	J Gastrointest Oncol	2016	0.75